Vertex has presented NHS England with an “innovative long-term framework proposal” that hopes to secure access for all eligible patients to its current and future portfolio of cystic fibrosis (CF) medicines.
Top-line trial data unveiled by Janssen at the 2018 American Academy of Dermatology (AAD) Annual Meeting over the weekend indicate that the benefit of Tremfya in patients with severe plaque psoriasis is maintained in the long-term.
French drugmaker Sanofi has named NIHR Clinical Research Network Greater Manchester as its first UK Premier Site, marking a “landmark” clinical research partnership that will help accelerate R&D to address the medical need of patients.
The NHS has launched a new device in England designed to accelerate the diagnosis of atrial fibrillation (AF), the most common arrhythmia and a contributing factor of up to one in five strokes in the UK.
Bristol-Myers Squibb and Nektar Therapeutics have signed a deal to develop and commercialise the latter’s lead immuno-oncology programme, NKTR-214, in combination with other anticancer therapies, on the back of the success of a previous clinical trials pact.